McCormack Lucas, Petrowsky Henrik, Jochum Wolfram, Mullhaupt Beat, Weber Markus, Clavien Pierre-Alain
Swiss HPB (Hepato-Pancreato-Biliary) Center, Department of Surgery, University Hospital Zurich, Switzerland.
Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8. doi: 10.1097/SLA.0b013e31815c2a3f.
Although there is a worldwide need to expand the pool of available liver grafts, cadaveric livers with severe steatosis (>60%) are discarded for orthotopic liver transplantation (OLT) by most centers.
We analyzed patients receiving liver grafts with severe steatosis between January 2002 and September 2006. These patients were matched 1:2 with control patients without severe steatosis according to status the waiting list, recipient age, recipient body mass index (BMI), and model for end-stage liver disease (MELD) score. Primary end points were the incidence of primary graft nonfunction (PNF), and graft and patient survival. Secondary end points included primary graft dysfunction (PDF), the incidence of postoperative complications, and histologic assessment of steatosis in follow-up biopsies. We also conducted a survey on the use of grafts with severe steatosis among leading European liver transplant centers.
During the study period, 62 patients dropped out of the waiting list and 45 of them died due to progression of disease. Of 118 patients who received transplants 20 (17%) received a graft with severe steatosis during this period. The median degree of total liver steatosis was 90% (R = 65%-100%) for the steatotic group. The steatotic (n = 20) and matched control group (n = 40) were comparable in terms of recipient age, BMI, MELD score, and cold ischemia time. The steatotic group had a significantly higher rate of PDF and/or renal failure. Although the median intensive care unit (ICU) and hospital stay were not significantly different between both groups, the proportion of patients with long-term ICU (> or =21 days) and hospital (> or =40 days) stay was significantly higher for patients with a severely steatotic graft. Sixty-day mortality (5% vs. 5%) and 3-year patient survival rate (83% vs. 84%) were comparable between the control and severe steatosis group. Postoperative histologic assessment demonstrated that the median total amount of liver steatosis decreased significantly (median: 90% to 15%, P < 0.001). Our survey showed that all but one of the European centers currently reject liver grafts with severe steatosis for any recipient.
Due to the urgent need of liver grafts, severely steatotic grafts should be no longer discarded for OLT. Maximal effort must be spent when dealing with these high-risk organs but the use of severely steatotic grafts may save the lives of many patients who would die on the waiting list.
尽管全球都需要扩大可用肝脏移植物的储备,但大多数中心都将严重脂肪变性(>60%)的尸体肝脏弃用于原位肝移植(OLT)。
我们分析了2002年1月至2006年9月期间接受严重脂肪变性肝脏移植物的患者。根据等待名单状态、受者年龄、受者体重指数(BMI)和终末期肝病模型(MELD)评分,将这些患者与无严重脂肪变性的对照患者按1:2进行匹配。主要终点是原发性移植物无功能(PNF)的发生率、移植物和患者生存率。次要终点包括原发性移植物功能障碍(PDF)、术后并发症的发生率以及随访活检中脂肪变性的组织学评估。我们还对欧洲主要肝脏移植中心使用严重脂肪变性移植物的情况进行了调查。
在研究期间,62名患者从等待名单中退出,其中45人因疾病进展死亡。在118名接受移植的患者中,有20名(17%)在此期间接受了严重脂肪变性的移植物。脂肪变性组肝脏总脂肪变性的中位程度为90%(范围=65%-100%)。脂肪变性组(n = 20)和匹配的对照组(n = 40)在受者年龄、BMI、MELD评分和冷缺血时间方面具有可比性。脂肪变性组PDF和/或肾衰竭的发生率显著更高。尽管两组之间重症监护病房(ICU)和住院时间的中位数没有显著差异,但严重脂肪变性移植物患者长期入住ICU(≥21天)和住院(≥40天)的比例显著更高。对照组和严重脂肪变性组的60天死亡率(5%对5%)和3年患者生存率(83%对84%)相当。术后组织学评估显示肝脏脂肪变性总量的中位数显著下降(中位数:90%至15%,P < 0.001)。我们的调查显示,除一个中心外,所有欧洲中心目前都拒绝将严重脂肪变性的肝脏移植物用于任何受者。
由于对肝脏移植物的迫切需求,严重脂肪变性的移植物不应再被弃用于OLT。在处理这些高风险器官时必须尽最大努力,但使用严重脂肪变性的移植物可能挽救许多将在等待名单上死亡的患者的生命。